PSTV — Plus Therapeutics Inc

Plus Therapeutics Inc (PSTV) is a biotechnology company listed on NASDAQ. It is led by Marc H. Hedrick M.B.A., M.D., based in 6420 LEVIT GREEN BOULEVARD, Houston, TX, United States, 77021, with about 28 employees. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Latest reported PSTV revenue for 2025-09-30 was $1.4M. Net income was -$4.4M. Revenue was up 0.5% from 2025-06-30 to 2025-09-30. PSTV currently screens at market cap $29.7M and trailing P/E 0.2.

Use this PSTV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PSTV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PSTV SEC filings page. Lician reads the product cache first so this HTML stays unique to Plus Therapeutics Inc even when a live quote feed is slow.